Using Misoprostol to Prevent Cervical Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial involves a double-blind randomized controlled approach with 420 non-pregnant women who are undergoing cervical cancer screening using visual inspection with acetic acid. Participants diagnosed with Type 3 transformation zone (TZ) will be randomly assigned to receive either Misoprostol or a placebo. The goal is to evaluate the effectiveness of Misoprostol in optimizing the prevention of cervical cancer in this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of Type 3 TZ confirmed on exam prior to randomization
* Age 25 years or older

Exclusion Criteria:

* With Type 1 or 2 TZ prior to randomization
* Currently pregnant
* History of hysterectomy
* Any cancerous lesions
* Active cervicitis

Where it's running

• Cameroon Baptist Convention Health Core, EtougEbe Baptist Hospital Yaoundé
  Yaoundé, Center Region, Cameroon Recruiting

Study contacts

• Principal investigator: Warner K Huh, MD — University of Alabama at Birmingham
• Study coordinator: Warner K Huh, MD
• Email: whuh@uabmc.edu
• Phone: 2059341555

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Moderately hypofractionated radiotherapy after hysterectomy for cervical cancer

  This study tests whether a shorter, moderately intensified radiotherapy course after surgery is safe and effective for patients with cervical cancer.

  Recruiting at 2 sites Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality and 1 other locations · NCT07684508

• Ivonescimab with paclitaxel and cisplatin before type A hysterectomy for Stage IB2/IIA1 (2–4 cm) cervical cancer

  This trial will test whether adding ivonescimab to paclitaxel and cisplatin before surgery helps women with 2–4 cm (Stage IB2 or IIA1) cervical cancer shrink tumors so they can have a less radical (type A) hysterectomy.

  Recruiting Phase 2 Obstetrics & Gynecology Hospital of Fudan University · Shanghai · NCT07130240

• 3- vs 4-fraction high-dose-rate brachytherapy for cervical cancer

  This will test whether a three-fraction high-dose-rate brachytherapy schedule works as well as the standard four-fraction schedule for adults with locally advanced cervical cancer.

  Recruiting Phase 2 Stanford University · Palo Alto, California · NCT07022470

• Neoadjuvant immunochemotherapy for locally advanced cervical cancer

  This trial will test whether giving paclitaxel and carboplatin together with a PD‑1/PD‑L1 immune checkpoint inhibitor before definitive treatment helps shrink tumors in patients with locally advanced cervical cancer (FIGO IB3–IIB) with tumors larger than 4 cm.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07003620

• IDOV-Immune for advanced solid tumors

  This trial will try a single IV infusion of an engineered oncolytic vaccinia virus called IDOV-Immune in adults with advanced solid tumors that no longer respond to standard treatments.

  Recruiting at 5 sites Phase 1 ViroMissile, Inc. · St Louis, Missouri and 4 other locations · NCT06910657

• Combination of Iparomlimab and Tuvonralimab with Chemotherapy for Cervical Cancer

  This study is testing whether combining two new immune treatments with standard chemotherapy can help women with locally advanced cervical cancer respond better to treatment before surgery.

  Recruiting Phase 2 Obstetrics & Gynecology Hospital of Fudan University · Shanghai · NCT06878222

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.